Kenneth Smith
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Kenneth Smith
Do Analysts See Any Upside for Thermo Fisher Stock?
Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”
Understanding Thermo Fisher Scientific’s Operational Performance
In this year’s third quarter, Thermo Fisher Scientific’s (TMO) selling, general, and administrative expenses rose YoY (year-over-year) to $1.49 billion from $1.40 billion.
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Taking Stock of Thermo Fisher as the Year Wraps Up
In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.
Do Analysts See Any Upside in BeiGene Stock?
Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
Understanding BeiGene’s Operational Performance
In its most recent quarter, BeiGene’s selling, general, and administrative expenses rose YoY (year-over-year) to $48.82 million.
Assessing BeiGene Limited’s Gross Margin Trend
In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million.
Taking Stock of BeiGene’s Latest Performance
BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Examining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.